adMare
News
December 03 2025
Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
November 20 2025
Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure
October 28 2025
Domain Therapeutics Doses First Patients in Phase I/II Trial of DT-7012 Targeting CCR8 in Solid Tumors
September 18 2025
Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy
September 17 2025
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
September 09 2025
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer
September 08 2025
Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025
July 10 2025
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
May 27 2025
Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC
May 01 2025
Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing
April 10 2025
Two key experts joining Find Therapeutics to accelerate the development of FTX-101
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.364.1220
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 415
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
